Table of Content

Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL DRAVET SYNDROME THEREAPEUTICS INDUSTRY
2.1 Summary about Dravet Syndrome Thereapeutics Industry
2.2 Dravet Syndrome Thereapeutics Market Trends
2.2.1 Dravet Syndrome Thereapeutics Production & Consumption Trends
2.2.2 Dravet Syndrome Thereapeutics Demand Structure Trends
2.3 Dravet Syndrome Thereapeutics Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 BIS-001
4.2.2 Cannabidiol
4.2.3 CUR-1916
4.2.4 SAGE-217
4.2.5 Others
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Clinic
4.3.2 Hospital
4.3.3 Others
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 BIS-001
5.2.2 Cannabidiol
5.2.3 CUR-1916
5.2.4 SAGE-217
5.2.5 Others
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Clinic
5.3.2 Hospital
5.3.3 Others
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 BIS-001
6.2.2 Cannabidiol
6.2.3 CUR-1916
6.2.4 SAGE-217
6.2.5 Others
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Clinic
6.3.2 Hospital
6.3.3 Others
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 BIS-001
7.2.2 Cannabidiol
7.2.3 CUR-1916
7.2.4 SAGE-217
7.2.5 Others
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Clinic
7.3.2 Hospital
7.3.3 Others
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 BIS-001
8.2.2 Cannabidiol
8.2.3 CUR-1916
8.2.4 SAGE-217
8.2.5 Others
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Clinic
8.3.2 Hospital
8.3.3 Others
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 BIS-001
9.2.2 Cannabidiol
9.2.3 CUR-1916
9.2.4 SAGE-217
9.2.5 Others
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Clinic
9.3.2 Hospital
9.3.3 Others
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Biscayne Pharmaceuticals, Inc.
10.1.2 GW Pharmaceuticals Plc
10.1.3 INSYS Therapeutics, Inc.
10.1.4 OPKO Health, Inc.
10.1.5 PTC Therapeutics, Inc.
10.1.6 Sage Therapeutics, Inc.
10.1.7 Xenon Pharmaceuticals Inc.
10.1.8 Zogenix, Inc.
10.2 Dravet Syndrome Thereapeutics Sales Date of Major Players (2017-2020e)
10.2.1 Biscayne Pharmaceuticals, Inc.
10.2.2 GW Pharmaceuticals Plc
10.2.3 INSYS Therapeutics, Inc.
10.2.4 OPKO Health, Inc.
10.2.5 PTC Therapeutics, Inc.
10.2.6 Sage Therapeutics, Inc.
10.2.7 Xenon Pharmaceuticals Inc.
10.2.8 Zogenix, Inc.
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT

List of Figure

List of Table
Table Dravet Syndrome Thereapeutics Product Type Overview
Table Dravet Syndrome Thereapeutics Product Type Market Share List
Table Dravet Syndrome Thereapeutics Product Type of Major Players
Table Brief Introduction of Biscayne Pharmaceuticals, Inc.
Table Brief Introduction of GW Pharmaceuticals Plc
Table Brief Introduction of INSYS Therapeutics, Inc.
Table Brief Introduction of OPKO Health, Inc.
Table Brief Introduction of PTC Therapeutics, Inc.
Table Brief Introduction of Sage Therapeutics, Inc.
Table Brief Introduction of Xenon Pharmaceuticals Inc.
Table Brief Introduction of Zogenix, Inc.
Table Products & Services of Biscayne Pharmaceuticals, Inc.
Table Products & Services of GW Pharmaceuticals Plc
Table Products & Services of INSYS Therapeutics, Inc.
Table Products & Services of OPKO Health, Inc.
Table Products & Services of PTC Therapeutics, Inc.
Table Products & Services of Sage Therapeutics, Inc.
Table Products & Services of Xenon Pharmaceuticals Inc.
Table Products & Services of Zogenix, Inc.
Table Market Distribution of Major Players
Table Global Major Players Sales Revenue (Million USD) 2017-2020e
Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e
Table Global Dravet Syndrome Thereapeutics Market Forecast (Million USD) by Region 2021f-2026f
Table Global Dravet Syndrome Thereapeutics Market Forecast (Million USD) Share by Region 2021f-2026f
Table Global Dravet Syndrome Thereapeutics Market Forecast (Million USD) by Demand 2021f-2026f
Table Global Dravet Syndrome Thereapeutics Market Forecast (Million USD) Share by Demand 2021f-2026f